Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
HRC vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. ABT: Which Stock Is the Better Value Option?
PerkinElmer (PKI) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
PerkinElmer (PKI) introduces test for the detection of coronavirus after it receives EUA for the same.
OPKO's BioReference Laboratories Widens COVID-19 Testing (Revised)
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
OPKO's BioReference Laboratories Widens COVID-19 Testing
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
Abbott Launches Coronavirus Detection Test After FDA Gives EUA
by Zacks Equity Research
Abbott (ABT) launches test for the detection of coronavirus in human, after receiving the EUA.
Abbott (ABT) Stock Moves -0.29%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $79.26 in the latest trading session, marking a -0.29% move from the prior day.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories
Coronavirus Ails S&P 500 Index, MedTechs Bear the Brunt
by Urmimala Biswas
S&P 500 MedTech stocks pull the index further down on COVID-19 situation becoming grimmer.
HRC vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HRC vs. ABT: Which Stock Is the Better Value Option?
Neovasc (NVCN) Releases Update on Reducer and Tiara Products
by Zacks Equity Research
Neovasc (NVCN) expects an approval from the FDA for Reducer by end of 2020.
Abbott (ABT) Stock Moves -1.91%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $80.52 in the latest trading session, marking a -1.91% move from the prior day.
Coronavirus Spreads Rapidly Worldwide: Medtech Stocks in Focus
by Aparajita Dutta
The coronavirus outbreak disrupts manufacturing and supply chain in China, which in turn might have taken a toll on U.S. Medtech stocks.
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
Medical Products Industry Outlook: Growth Prospects Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.
Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On
by Sriparna Ghosal
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
Abbott's Alliance With Insulet to Fortify Diabetic Care Unit
by Zacks Equity Research
Both Abbott (ABT) and Insulet will use a pay-as-you-go model to enhance customer acceptance.
Insulet Partners With Dexcom for Automated Insulin Delivery
by Zacks Equity Research
This agreement is a major step forward in Insulet's (PODD) commitment toward bolstering its automated insulin delivery system and providing better clinical outcomes for diabetes patients.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Trina Mukherjee
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Sonoco (SON) Meets Q4 Earnings Estimates
by Zacks Equity Research
Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More
by Urmimala Biswas
Strong foothold in the emerging markets so far widely contributes to some of the industry players' Q4 results.
Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
Breaking Q4 Earnings News
by Zacks Equity Research
Breaking Q4 Earnings News
Chicago Econ Numbers & More Q4 Earnings: JNJ, ABT, FITB
by Mark Vickery
Certain weeks of the year are rife with important information for the stock market. This is not one of those weeks.
Abbott (ABT) Q4 Earnings Match Estimates, Revenues Beat Mark
by Zacks Equity Research
We are upbeat about Abbott's (ABT) strong and consistent EPD and Medical Devices performances, organically.
Abbott (ABT) Meets Q4 Earnings Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 0.00% and 0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?